目的 探討芪藶強(qiáng)心膠囊聯(lián)合瑞舒伐他汀鈣片治療急性心肌梗死的臨床療效。方法 選取2018年2月-2020年8月洛陽(yáng)石化醫(yī)院收治的76例急性心肌梗死患者，根據(jù)隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各38例。對(duì)照組口服瑞舒伐他汀鈣片，10 mg/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服芪藶強(qiáng)心膠囊，4粒/次，3次/d。兩組患者連續(xù)治療4周。觀察兩組的臨床療效，比較治療前后心功能指標(biāo)和血清因子水平。結(jié)果 治療后，治療組的總有效率為94.74%，對(duì)照組的總有效率為78.95%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的左心室射血分?jǐn)?shù)（LVEF）、內(nèi)皮依賴性血管舒張功能（FMD）明顯升高，左心室收縮末期內(nèi)徑（LVESD）明顯降低（P<0.05）；且治療后治療組的LVEF、FMD高于對(duì)照組，LVESD低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的超敏C反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）、腦鈉肽（BNP）、α-羥丁酸脫氫酶（α-HBD）水平顯著降低（P<0.05）；且治療后治療組的hs-CRP、TNF-α、BNP、α-HBD水平低于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 芪藶強(qiáng)心膠囊聯(lián)合瑞舒伐他汀鈣片可提高急性心肌梗死的臨床療效，改善心功能，減輕炎癥反應(yīng)，安全性良好。

Objective To investigate the clinical effect of Qili Qiangxin Capsules combined with Rosuvastatin Calcium Tablets in treatment of acute myocardial infarction. Methods Patients (76 cases) with acute myocardial infarction in Luoyang Petrochemical Hospital from February 2018 to August 20120 were randomly divided into control and treatment groups, and each group had 38 cases. Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and cardiac function index and serum factor levels in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.74%, and that of the control group was 78.95%, and the difference between two groups was statistically significant (P<0.05). After treatment, LVEF and FMD of two groups were significantly increased, but LVESD of two groups was significantly decreased (P<0.05). After treatment, LVEF and FMD of the treatment group were higher than those of the control group, but LVESD of the treatment group was lower than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of hs-CRP, TNF-α, BNP, and α-HBD in two groups were significantly decreased (P<0.05). And after treatment, the levels of hs-CRP, TNF-α, BNP, and α-HBD in the treatment group were lower than those in the control group, the difference was statistically significant (P<0.05). Conclusion Qili Qiangxin Capsules combined with Rosuvastatin Calcium Tablets can improve the clinical efficacy of acute myocardial infarction, improve cardiac function, reduce inflammatory reaction, with good safety.

R972

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（LHGJ20191210）